Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02715297 : Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma
PhasePhase 2
AgesMin: 18 Years Max: 99 Years
Eligibility
Inclusion Criteria:

- Unifocal, supratentorial recurrent glioblastoma

- Prior course of standard treatment

- Complete resection of all contrast enhancing areas

- age = 18 years of age

- Karnofsky Performance Score 60% or higher

- For women with childbearing potential, (and men) adequate contraception.

- Ability of subject to understand character and individual consequences of the clinical
trial

- Written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

- Multifocal glioblastoma of gliomatosis cerebri

- Time interval of less than 6 months after primary radiotherapy

- Previous re-irradiation or prior radiosurgery of prior treatment with interstitial
radioactive seeds

- refusal of the patients to take part in the study

- Patients who have not yet recovered from acute toxicities of prior therapies

- Known carcinoma < 5 years ago (excluding Carcinoma in situ of the cervix, basal cell
carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment
interfering with study therapy

- Pregnant or lactating women

- Participation in another clinical study or observation period of competing trials,
respectively.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02715297      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740